Biohaven Ltd stock is traded at $13.80, with a volume of 2,347,445. It is up +6.98% in the last 24 hours and up +21.59% over the past month. Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
Previous Close:
$12.90
Open:
$13.24
24h Volume:
2,347,445
Relative Volume:
1.07
Market Cap:
$2.08B
Revenue:
$737.54M
Net Income/Loss:
-$647.68M
P/E Ratio:
-
EPS:
-$5.67
Net Cash Flow:
-$594.49M
1W Performance:
-1.92%
1M Performance:
+21.59%
6M Performance:
+64.48%
1Y Performance:
+45.88%
1-Day Range:
$13.00$14.27
1-Week Range:
$12.87$14.29
52-Week Range:
$8.03$18.24
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven LtdSector
HealthcareIndustry
BiotechnologyPhone
203-404-0410Address
215 CHURCH STREET, NEW HAVEN, CT, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS